Vasculitis Video Perspectives

In this conversation, a rheumatologist and nephrologist from the University of North Carolina talked about the management of patients with vasculitis from a collaborative care framework.

“They get a lot of attention in that visit, and we put our heads together and we make treatment decisions at the same time,” said Nicole M. Orzechowski, DO, RhMSUS, associate professor of medicine and medical director of the UNC Rheumatology Clinic. “I think that it benefits patients.”

“This multidisciplinary clinic we’ve been able to establish this last couple years has probably been one of the most rewarding experiences I’ve had professionally,” added Vimal K. Derebail, MD, MPH, FASN, associate professor of medicine and nephrology lead of the UNC Multidisciplinary Vasculitis and Connective Tissue Disease Clinic.

They also discussed:

• the most recent FDA approval for vasculitis, highlighting some barriers of it being fully incorporated into practice;
• the differences in treating and managing ANCA-associated vasculitis compared with non-ANCA vasculitis; and
• challenges in the management of vasculitis.

References:

• Jayne DRW, et al. N Engl J Med. 2021;doi:10.1056/NEJMoa2023386.
• Walsh M, et al. N Engl J Med. 2020;doi:10.1056/NEJMoa1803537.

Disclosure:

Orzechowski reports no relevant financial disclosures. Derebail reports serving on advisory boards for Amgen, Bayer, Merck and Travere Therapeutics; and consulting for Novartis and Novo Nordisk (Forma Therapeutics).